PMDD Treatment: What the Science Actually Shows

The most common thing women hear about premenstrual dysphoric disorder is that it’s a hormone imbalance. Too much estrogen, not enough progesterone, or some version of that story. It’s a clean explanation, and patients are often told to get their hormone levels checked to confirm it. Here’s the problem. When you measure the hormones for PMDD treatment, they come back normal.

PMDD is real, it’s often severe, and the psychiatry behind it is well studied. But the mechanism sits in how the brain responds to the normal hormone shifts of a normal menstrual cycle. The levels themselves are ordinary. That distinction isn’t academic. It changes how PMDD gets diagnosed, why the bloodwork your doctor ordered won’t show it, and which treatments actually work.

This is a guide to what the evidence shows and how I approach PMDD in my North Carolina telehealth practice. If you want an evaluation rather than an explanation, you can book a consultation or read more about the psychiatry services I offer.

---

What PMDD actually is, and what separates it from PMS

Premenstrual dysphoric disorder is a cyclical mood disorder tied to the luteal phase, the roughly two weeks between ovulation and your period. Symptoms appear in that window, get worse as the period approaches, and then lift within a few days of bleeding starting. The pattern is the diagnosis. Symptoms that run all month long are not PMDD, even when they flare premenstrually.

The DSM-5-TR sets a specific bar. You need at least 5 of 11 symptoms in the final week before menses, and at least one has to be a core mood symptom: marked irritability or anger, sudden sadness or tearfulness, anxiety or tension, or a depressed, hopeless mood. The rest can be physical or behavioral, things like breast tenderness, bloating, sleep disruption, appetite change, fatigue, or feeling overwhelmed and out of control. The symptoms have to cause real impairment at work, at home, or in relationships.

That impairment line is what separates PMDD from ordinary premenstrual syndrome. Most menstruating women notice some premenstrual symptoms. PMDD is the severe end, where the week before your period reliably damages your functioning and your relationships. Prevalence estimates land between 2 and 5 percent of menstruating women when the diagnosis is applied strictly, which makes it roughly as common as conditions psychiatry treats every day.

The hormone imbalance myth: your levels are supposed to be normal

The cleanest evidence here is old and still definitive. In 1998, Peter Schmidt and David Rubinow at the National Institute of Mental Health published a study in the New England Journal of Medicine that took women with confirmed PMS and shut their ovaries down with leuprolide, a drug that suppresses the cycle. Symptoms went away. Then the researchers added back estradiol or progesterone, one at a time, in a blinded design. Symptoms came roaring back. The women without PMS felt nothing during either manipulation (PMID: 9435325).

The same hormones, at the same normal doses, triggered symptoms in one group and did nothing in the other. Both groups had ordinary hormone levels. What differed was how their brains reacted to them. Schmidt’s team confirmed and extended this in 2017, showing that the trigger is the change in steroid levels rather than a stable abnormal level (PMID: 28427285).

The current mechanism points to a progesterone metabolite called allopregnanolone. Allopregnanolone is one of the most potent modulators of the GABA-A receptor in the brain, the same receptor that benzodiazepines and alcohol act on. In PMDD, the GABA-A system appears to respond abnormally to the ordinary luteal rise in allopregnanolone, producing irritability, anxiety, and dysphoria instead of the calming effect you’d expect. The hormones are doing what they always do. The receptor is what’s tuned wrong.

If this sounds familiar, it should. Psychiatry told patients for decades that depression was a serotonin deficit, and that story collapsed under scrutiny too. I’ve written about what the science actually shows on the chemical imbalance theory of depression. PMDD is the same lesson in a different system. The popular explanation is a simple imbalance. The real mechanism is a sensitivity, and that’s the part that matters for treatment.

PMDD, PMS, and premenstrual exacerbation are three different things

This is where a lot of treatment goes wrong, in both directions. PMS is the mild-to-moderate version that most women have and most women manage. PMDD is the severe, impairing, diagnosable form. And then there’s a third category that gets confused with both: premenstrual exacerbation, where an underlying psychiatric condition gets worse in the luteal phase.

If you are trying to place yourself, I break the categories down in a dedicated guide to PMDD vs PMS, and the third category most comparisons miss.

The distinction is clinical, not semantic. A woman with bipolar disorder or recurrent major depression often feels her symptoms intensify premenstrually. That’s premenstrual exacerbation of an existing illness, and it’s not PMDD, because the symptoms don’t clear after the period. Treating it as PMDD means missing the real diagnosis. Going the other way, a woman with true PMDD sometimes gets labeled bipolar because of the dramatic monthly mood swings, then started on a mood stabilizer she doesn’t need.

Getting this right matters because the treatments diverge. PMDD responds to interventions aimed at the cycle. A premenstrual flare of bipolar disorder needs the bipolar treated. The only way to tell them apart is to look at what the symptoms do across the whole month, which brings up the single most skipped step in PMDD care.

Why a real diagnosis needs two cycles of daily tracking

The DSM-5-TR requires prospective daily ratings across at least two symptomatic cycles to confirm PMDD. Prospective means you rate symptoms as they happen, day by day, not from memory at the doctor’s office. This requirement exists for a concrete reason: retrospective recall is unreliable. When researchers compare what women remember against what they actually log day to day, a large share of presumed PMDD turns out to be something else, often a mood disorder that runs all month.

The standard tool is the Daily Record of Severity of Problems, scored with a validated algorithm called the Carolina Premenstrual Assessment Scoring System. In validation work it diagnosed PMDD with about 98 percent accuracy against expert assessment (PMID: 27523500). Two cycles of honest daily rating will tell you, and your clinician, whether your symptoms truly track the luteal phase or whether they’re present at a lower level all the time.

The two cycles of tracking are the difference between treating PMDD and treating a label. If you’ve been told you have PMDD but never charted a cycle, the diagnosis hasn’t actually been made yet. You can book an evaluation and we’ll start with the data.

How serious PMDD gets, and why it isn’t “just moody”

PMDD is frequently dismissed as exaggerated PMS. The suicide data says otherwise. In a sample of women with prospectively confirmed PMDD, 39 percent reported current suicidal ideation when assessed in the late luteal phase (PMID: 35148753). That rate is in the range seen in major depressive disorder. The risk isn’t spread evenly across the month either; it concentrates in the days before menses, which is exactly when a cyclical disorder would predict it.

I go deeper on this in a dedicated guide on PMDD and suicidal thoughts, including why the risk peaks premenstrually and what lowers it.

Two things follow from that. First, PMDD deserves to be treated as a serious psychiatric condition, not managed with reassurance and a heating pad. Second, the timing is usable clinically. If your worst days are predictable, the danger window is predictable, and treatment and safety planning can be built around it. Predictability is one of the few advantages a cyclical disorder offers, and good care uses it.

If you’re having thoughts of suicide, you don’t have to wait for a cycle to chart. In the United States you can call or text 988 to reach the Suicide and Crisis Lifeline at any hour.

SSRIs for PMDD work, and they work differently than they do for depression

Selective serotonin reuptake inhibitors are the first-line medical treatment for PMDD, and the evidence is strong. A Cochrane review of trials covering more than 2,000 women found SSRIs clearly reduced premenstrual symptoms compared with placebo (PMID: 23744611). Three are FDA approved specifically for PMDD: fluoxetine, sertraline, and controlled-release paroxetine.

Sertraline is the SSRI most often used for PMDD, and coming off it has its own course, covered in Zoloft withdrawal.

In PMDD, SSRIs often work within a day or two, not the 2 to 4 weeks they take in depression. That fast response is a clue about mechanism. Beyond blocking serotonin reuptake, SSRIs rapidly increase the brain’s production of allopregnanolone, the same neurosteroid implicated in the disorder. The speed is why a treatment strategy that makes no sense in depression works well here: luteal-phase dosing.

Luteal dosing means taking the SSRI only during the symptomatic two weeks, then stopping during the rest of the cycle. It was first shown to work in a controlled trial back in 1998 (PMID: 9501889), and it remains a legitimate option today. Some women do better with continuous daily dosing, and some use a symptom-onset approach, starting the medication when symptoms appear each cycle, though the evidence for symptom-onset timing is somewhat weaker than for luteal or continuous dosing (PMID: 26351969). Which schedule fits depends on how regular your cycle is and how your symptoms behave.

A few honest caveats. SSRIs have side effects, including sexual side effects that can persist, which I cover in my piece on post-SSRI sexual dysfunction. And stopping an SSRI deserves a plan rather than an abrupt halt, especially with shorter-acting agents; my guide on how to taper off an SSRI walks through that. SSRIs are still the right first-line choice for most PMDD. These caveats are about prescribing them deliberately, with the tradeoffs on the table.

Hormonal and other options, and where they fit

SSRIs aren’t the only route. Because PMDD is driven by the cyclical hormone change, suppressing or smoothing that cycle helps some women. These options sit largely with your gynecologist or primary care team, and I’ll often coordinate care rather than manage them directly, but you should know they exist.

A combined oral contraceptive containing drospirenone and ethinyl estradiol on a 24/4 schedule is FDA approved for PMDD and is a reasonable first-line option for women who also want contraception. For severe, treatment-resistant cases, GnRH agonists with hormonal add-back can switch the cycle off almost entirely, an approach reserved for when first-line treatments have failed because of cost and the need for add-back to protect bone density. Lifestyle measures, including exercise, sleep regularity, and reducing alcohol in the luteal phase, are worth doing but rarely sufficient on their own for true PMDD. Several supplements have real trial evidence as well, calcium most of all, and cognitive behavioral therapy holds up about as well as medication for the mood symptoms. I grade the over-the-counter and non-drug options in a companion guide on natural treatments for PMDD and what the evidence supports.

There’s also a treatment on the horizon worth watching. Sepranolone is an experimental agent designed to block allopregnanolone’s action at the GABA-A receptor, hitting the proposed mechanism head on. An early controlled trial reported meaningful symptom reduction with a good safety profile (PMID: 28319848). It isn’t approved or available yet, but it’s a sign that the sensitivity model is producing real drug targets.

How I approach PMDD in my North Carolina practice

PMDD is a good fit for telehealth. The diagnosis depends on tracking rather than a physical exam, and the treatment is medication management plus close follow-up. I see patients throughout North Carolina by video, which means the two cycles of daily rating happen in your real life, on your phone, and we review them together.

The first job is making sure it’s actually PMDD. We chart at least two cycles before committing to a diagnosis, because I’m not going to treat a label. That step also catches the cases that are really premenstrual exacerbation of an underlying mood or anxiety disorder, which changes the whole plan. If anxiety is running alongside the cyclical symptoms, my work on treating anxiety in North Carolina is relevant to how I’d structure care.

From there, treatment is individualized. For many women that’s an FDA-approved SSRI, dosed luteally or continuously depending on the cycle, with the side-effect tradeoffs discussed openly rather than glossed over. For others it’s coordinating with their gynecologist on a hormonal approach. The hormone-mood connection runs in both sexes, and I treat the male side of it too, including low testosterone and depression. PMDD is the same principle on the female side: get the mechanism right, and the treatment follows.

---

Frequently asked questions

Can a blood test diagnose PMDD?

No. Women with PMDD have normal hormone levels, so bloodwork won’t confirm it and a normal panel doesn’t rule it out. PMDD is a brain sensitivity to normal cyclical hormone changes, not an abnormal level. The diagnosis is made by tracking symptoms prospectively across at least two menstrual cycles to confirm they rise in the luteal phase and clear after menses.

Is PMDD a hormone imbalance?

Not in the usual sense. Controlled studies show that the same normal hormone levels trigger symptoms in women with PMDD and no symptoms in women without it, so the issue is the brain’s response to ordinary hormone shifts rather than a level that’s too high or too low. The leading mechanism involves altered sensitivity of the GABA-A receptor to allopregnanolone, a progesterone metabolite.

How is PMDD different from PMS?

PMS is the mild-to-moderate premenstrual symptoms most menstruating women experience. PMDD is the severe form that causes real impairment in work, relationships, or daily functioning, and it requires at least 5 of 11 specific symptoms with at least one core mood symptom under DSM-5-TR. The line between them is severity and the degree of disruption, not the type of symptom.

Do antidepressants for PMDD have to be taken every day?

Not necessarily. Because SSRIs often work within a day or two for PMDD rather than the weeks they take for depression, many women can dose only during the luteal phase, the roughly two weeks before the period, and stop the rest of the cycle. Others do better with continuous daily dosing. The right schedule depends on how regular your cycle is and how your symptoms behave, and it’s a decision to make with your prescriber.

Can PMDD be treated through telehealth in North Carolina?

Yes. PMDD diagnosis relies on symptom tracking rather than a physical exam, and treatment is medication management with regular follow-up, both of which work well by video. I evaluate and treat PMDD for patients across North Carolina through telehealth, starting with two cycles of daily symptom rating to confirm the diagnosis before treatment.

---

This article is for educational purposes only and is not medical advice. It does not create a physician-patient relationship. PMDD, depression, and related conditions require individual evaluation. Do not start, stop, or change any medication without consulting your prescribing clinician. If you are in crisis or thinking about harming yourself, call or text 988 in the United States to reach the Suicide and Crisis Lifeline.

---

References

1. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338(4):209-216. PMID: 9435325.
2. Schmidt PJ, Martinez PE, Nieman LK, et al. Premenstrual dysphoric disorder symptoms following ovarian suppression: triggered by change in ovarian steroid levels but not continuous stable levels. Am J Psychiatry. 2017;174(10):980-989. PMID: 28427285.
3. Eisenlohr-Moul TA, Girdler SS, Schmalenberger KM, et al. Toward the reliable diagnosis of DSM-5 premenstrual dysphoric disorder: the Carolina Premenstrual Assessment Scoring System (C-PASS). Am J Psychiatry. 2017;174(1):51-59. PMID: 27523500.
4. Wikman A, Sacher J, Bixo M, et al. Prevalence and correlates of current suicidal ideation in women with premenstrual dysphoric disorder. BMC Womens Health. 2022;22(1):35. PMID: 35148753.
5. Marjoribanks J, Brown J, O’Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013;(6):CD001396. PMID: 23744611.
6. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry. 1998;59(2):76-80. PMID: 9501889.
7. Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(10):1037-1044. PMID: 26351969.
8. Bixo M, Ekberg K, Poromaa IS, et al. Treatment of premenstrual dysphoric disorder with the GABA-A receptor modulating steroid antagonist sepranolone (UC1010): a randomized controlled trial. Psychoneuroendocrinology. 2017;80:46-55. PMID: 28319848.
9. Moncrieff J, Cooper RE, Stockmann T, et al. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2023;28(8):3243-3256. PMID: 35854107.